Focused On-demand Libraries - Receptor.AI Collaboration


Explore the Potential with AI-Driven Innovation

The specialised, focused library is developed on demand with the most recent virtual screening and parameter assessment technology, guided by the Receptor.AI drug discovery platform. This approach exceeds the capabilities of traditional methods and offers compounds with higher activity, selectivity, and safety.


The compounds are cherry-picked from the vast virtual chemical space of over 60B molecules. The synthesis and delivery of compounds is facilitated by Reaxense.


The library includes a list of the most effective modulators, each annotated with 38 ADME-Tox and 32 physicochemical and drug-likeness parameters. Furthermore, each compound is shown with its optimal docking poses, affinity scores, and activity scores, offering a detailed summary.


Our high-tech, dedicated method is applied to construct targeted libraries for enzymes.


 

Fig. 1. The screening workflow of Receptor.AI

The method includes detailed molecular simulations of the catalytic and allosteric binding pockets, along with ensemble virtual screening that considers their conformational flexibility. In the design of modulators, structural changes induced by reaction intermediates are taken into account to enhance activity and selectivity.


Key features that set our library apart include:


  • The Receptor.AI platform integrates extensive information about the target protein, such as historical experiments, academic research, known ligands, and structural insights, thereby increasing the likelihood of identifying highly relevant compounds.

  • The platform’s sophisticated molecular simulations are designed to discover potential binding sites, ensuring that our focused library is optimal for the discovery of allosteric inhibitors and binders for cryptic pockets.

  • With over 50 customisable AI models, verified through extensive testing in commercial drug discovery and research, Receptor.AI is efficient, reliable, and precise. These models are essential in the production of our focused libraries.

  • Receptor.AI not only produces focused libraries but also provides full services and solutions at every stage of preclinical drug discovery, with a success-based pricing structure that aligns our interests with the success of your project.


PARTNER
Receptor.AI
 
UPACC
P27037

UPID:
AVR2A_HUMAN

ALTERNATIVE NAMES:
Activin receptor type IIA

ALTERNATIVE UPACC:
P27037; B2RAB8; B4DWQ2; D3DP85; Q53TH4; Q6NWV2; Q92474

BACKGROUND:
The Activin receptor type-2A, alternatively known as Activin receptor type IIA, is integral to the signaling mechanisms that regulate cellular growth and differentiation. It operates through a complex mechanism involving the phosphorylation of type I and type II serine/threonine kinase receptors, facilitating the activation of SMAD transcriptional regulators. This receptor is essential for the actions of activin A, activin B, and inhibin A, and is implicated in the induction of adipogenesis by GDF6.

THERAPEUTIC SIGNIFICANCE:
The exploration of Activin receptor type-2A's functions offers a promising avenue for the development of novel therapeutic approaches. Its key role in mediating important cellular processes highlights its potential as a therapeutic target in diseases related to abnormal cellular communication and growth.

Looking for more information on this library or underlying technology? Fill out the form below and we will be in touch with all the details you need.